Gilder Gagnon Howe & Co. LLC Sells 403,617 Shares of Quanterix Co. (NASDAQ:QTRX)

Gilder Gagnon Howe & Co. LLC lowered its stake in shares of Quanterix Co. (NASDAQ:QTRX - Free Report) by 85.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 68,663 shares of the company's stock after selling 403,617 shares during the period. Gilder Gagnon Howe & Co. LLC owned 0.18% of Quanterix worth $730,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of QTRX. Resona Asset Management Co. Ltd. purchased a new position in shares of Quanterix in the fourth quarter worth about $55,000. Tower Research Capital LLC TRC grew its stake in Quanterix by 219.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company's stock valued at $61,000 after buying an additional 3,915 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in Quanterix during the 4th quarter valued at $66,000. Canada Pension Plan Investment Board lifted its position in shares of Quanterix by 64.5% during the fourth quarter. Canada Pension Plan Investment Board now owns 10,200 shares of the company's stock worth $108,000 after acquiring an additional 4,000 shares in the last quarter. Finally, Peapack Gladstone Financial Corp bought a new position in shares of Quanterix in the third quarter worth $131,000. Institutional investors own 86.48% of the company's stock.

Quanterix Trading Up 4.2 %

Shares of NASDAQ QTRX traded up $0.24 during midday trading on Friday, hitting $6.01. 477,565 shares of the company's stock were exchanged, compared to its average volume of 553,056. The business's fifty day moving average price is $6.35 and its two-hundred day moving average price is $9.32. The company has a market cap of $233.12 million, a price-to-earnings ratio of -5.67 and a beta of 1.12. Quanterix Co. has a 12-month low of $4.67 and a 12-month high of $19.18.

Quanterix (NASDAQ:QTRX - Get Free Report) last released its quarterly earnings results on Monday, March 17th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.03). Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. The company had revenue of $35.16 million during the quarter, compared to analysts' expectations of $34.93 million. Equities analysts expect that Quanterix Co. will post -0.98 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on QTRX. Leerink Partners reissued a "market perform" rating and set a $8.00 price objective (down previously from $12.00) on shares of Quanterix in a report on Wednesday. Canaccord Genuity Group lowered their price target on shares of Quanterix from $20.00 to $15.00 and set a "buy" rating on the stock in a report on Tuesday, March 18th. Leerink Partnrs cut shares of Quanterix from a "strong-buy" rating to a "hold" rating in a research note on Wednesday. Finally, Scotiabank reiterated an "outperform" rating on shares of Quanterix in a research note on Tuesday, March 25th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $16.20.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.